Surgery Today

, Volume 46, Issue 12, pp 1394–1401 | Cite as

Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer

  • Takashi Suzuki
  • Hideaki ShimadaEmail author
  • Tatsuki Nanami
  • Yoko Oshima
  • Satoshi Yajima
  • Masaaki Ito
  • Naohiro Washizawa
  • Hironori Kaneko
Original Article



Hyperfibrinogenemia is associated with poor prognosis in various cancers; however, its clinical relevance in gastric cancer has not been well analyzed. We conducted this study to assess the clinicopathological significance and prognostic value of hyperfibrinogenemia in patients with gastric cancer.


Plasma fibrinogen levels were measured preoperatively in 315 patients undergoing surgery for gastric cancer. We then evaluated the clinicopathological significance of hyperfibrinogenemia and its relationship with several biomarkers, including white blood cell (WBC), C-reactive protein (CRP), platelet count, prothrombin time (PT) and activated partial thromboplastin time (APTT). Postoperative plasma levels were compared with preoperative levels. The multivariate prognostic value of hyperfibrinogenemia was calculated using the Cox proportional hazards model.


Tumor progression was significantly associated with hyperfibrinogenemia, as were the CRP level and platelet counts. Plasma fibrinogen levels decreased significantly after radical surgery. Adjusting for TNM factors, multivariate analysis indicated that hyperfibrinogenemia was an independent prognostic factor for poor survival (hazard ratio = 2.607, 95 % confidence interval = 1.180–5.761, P = 0.018).


Preoperative hyperfibrinogenemia was associated with tumor progression, inflammatory mediators, and poor overall survival in patients with gastric cancer.


Gastric cancer Plasma fibrinogen Hyperfibrinogenemia 



This work was partly supported by JSPS KAKENHI Grant Number 15K10117.

Compliance with ethical standards

Conflict of interest

We have no conflicts of interest to declare.

Supplementary material

595_2016_1339_MOESM1_ESM.docx (111 kb)
Supplementary material 1 (DOCX 111 kb)


  1. 1.
    Brown LF, Van de Water L, Harvey VS, Dvorak HE. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol. 1988;130:455–65.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22:302–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Qi Q, Geng Y, Sun M, Chen H, Wang P, Chen Z. Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in advanced pancreatic cancer. Pancreas. 2015;44:977–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma. Oncology. 2013;85:269–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Liu YL, Lu Q, Liang JW, et al. High plasma fibrinogen is correlated with poor response to trastumab treatment in HER2 positive breast cancer Liang B. Medicine (Baltimore). 2015;94:e481.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Son HJ, Park JW, Chang HJ, Kim DY, Kim BC, Kim SY, Park SC, Choi HS, Oh JH. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol. 2013;20:2908–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, et al. The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer. World J Urol. 2015;33:1467–73.CrossRefPubMedGoogle Scholar
  8. 8.
    Rickles FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost. 1988;14:88–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Hogg N. Human monocytes have prothrombin cleaving activity. Clin Exp Immunol. 1983;53:725–30.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Yamashita H, Kitayama J, Nagawa H, Yatomi Y, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol. 2005;35:595–600.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee SE, Lee JH, Ryu KW, Nam BH, Cho SJ, Lee JY, et al. Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer. J Gastric Cancer. 2012;12:81–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRefGoogle Scholar
  13. 13.
  14. 14.
    Kanai M, Okumura N, Tozuka M, Yatomi Y. 34 ed. Rinshou Kensahou Teiyou. Kanehara. 2015; p. 402.Google Scholar
  15. 15.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28:740–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Hu C, Chen R, Chen W, Pang W, Xue X, Zhu G, Shen X. Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med. 2014;8:125–32.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhao L, Feng S, Huang S, Tong Y, Chen Z, Wu P et al. Diagnostic value of hyperfibrinogenemia as a predictive factor for appendiceal perforation in acute appendicitis. ANZ J Surg. 2015. doi:  10.1111/ans.13316.Google Scholar
  19. 19.
    Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2015. doi: 10.1007/s00595-015-1236-x/.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  • Takashi Suzuki
    • 1
  • Hideaki Shimada
    • 1
    Email author
  • Tatsuki Nanami
    • 1
  • Yoko Oshima
    • 1
  • Satoshi Yajima
    • 1
  • Masaaki Ito
    • 1
  • Naohiro Washizawa
    • 1
  • Hironori Kaneko
    • 1
  1. 1.Department of Surgery, School of MedicineToho UniversityTokyoJapan

Personalised recommendations